Do you approach treatment any differently for a patient with prior early-stage hormone receptor positive breast cancer who experiences metastatic triple negative recurrence?

Community
Company
Programs
Contact Us
Sign in

Topics: Breast Cancer • Medical Oncology • NCI-CCC Tumor Board Question • Yale • Triple negative • NCI-CCC Breast Tumor Board Question • Breast Cancer, Metastatic

How does one's history of HR+ breast cancer influence treatment decision?

Patient has no new obvious primary.

Related Questions

How would you manage tucatinib-associated grade 2 indirect hyperbilirubinemia in a patient with metastatic HER2-positive breast cancer involving the CNS receiving trastuzumab + capecitabine + tucatinib?

How do you incorporate ctDNA in the management of metastatic breast cancer?

How would you manage patients with TNBC who achieve a pCR with neoadjuvant KEYNOTE-522 regimen, but develop isolated chest wall recurrence soon after completing neoadjuvant treatment?

How would you approach a young patient with oligometastatic inflammatory triple negative breast cancer with bone only metastases?

In light of SABCS 2022, when will you opt for a CDK 4/6 inhibitor plus AI instead of chemotherapy in patients with metastatic HR-positive HER2-negative breast cancer with visceral crisis?

Would you recommend olaparib for a patient with germline BRCA1 mutation and HER2+ metastatic breast cancer who has progressed through multiple lines of HER2-directed therapy including trastuzumab deruxtecan?

In terms of contraception, what do you recommend for patients with a history of hormone receptor-negative compared to hormone receptor-positive breast cancer?

In light of SABCS 2022, will you use BCI to guide OFS recommendation in the adjuvant setting?

In what circumstances would you stop therapy for patients with metastatic HER2+ breast cancer with long-term complete response to HER2-directed therapy?

In patients with localized triple-negative breast cancer and residual disease at time of surgery following neoadjuvant KEYNOTE-522 regimen, when would you recommend adding adjuvant capecitabine or another agent to pembrolizumab?